Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy

Breast Cancer Research and Treatment

Volumn 125, Issue 3, 2011, Pages 767-774

  Hershman, Dawn L ^a,b,c   Weimer, Louis H ^a   Wang, Antai ^b   Kranwinkel, Grace ^a   Brafman, Lois ^a   Fuentes, Deborah ^a   Awad, Danielle ^a   Crew, Katherine D ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b Columbia University ^*  (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cancer survivorship; Neurotoxicity; Patient reported outcomes

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVOR; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; ETHNICITY; FEMALE; FOOT DISEASE; FOOT PAIN; HAND DISEASE; HAND PARESTHESIA; HUMAN; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; SENSORY SYSTEM; SYMPTOMATOLOGY; TOUCH; VIBRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPESTHESIA; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; TAXOIDS;

EID: 79251514958     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1278-0     Document Type: Article

References (40)

1. IC Henderson DA Berry GD Demetri CT Cirrincione LJ Goldstein S Martino JN Ingle MR Cooper DF Hayes KH Tkaczuk, et al. 2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 6 976 983 1:CAS:528:DC%2BD2cXpsVGqs7c%3D 10.1200/JCO.2003.02.063 12637460 (Pubitemid 46594124)
2. M De Laurentiis G Cancello D D'Agostino M Giuliano A Giordano E Montagna R Lauria V Forestieri A Esposito L Silvestro, et al. 2008 Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol 26 1 44 53 10.1200/JCO.2007.11.3787 18165639
3. SE Jones MA Savin FA Holmes JA O'Shaughnessy JL Blum S Vukelja KJ McIntyre JE Pippen JH Bordelon R Kirby, et al. 2006 Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer J Clin Oncol 24 34 5381 5387 1:CAS:528:DC%2BD2sXisVSjtQ%3D%3D 10.1200/JCO.2006.06.5391 17135639 (Pubitemid 46623169)
4. SH Giordano Z Duan YF Kuo GN Hortobagyi J Freeman JS Goodwin 2006 Impact of a scientific presentation on community treatment patterns for primary breast cancer J Natl Cancer Inst 98 6 382 388 10.1093/jnci/djj090 16537830
5. R Pazdur AP Kudelka JJ Kavanagh PR Cohen MN Raber 1993 The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere) Cancer Treat Rev 19 4 351 386 1:CAS:528:DyaK2cXksFSisg%3D%3D 10.1016/0305-7372(93)90010-O 8106152 (Pubitemid 23333409)
6. S Quasthoff HP Hartung 2002 Chemotherapy-induced peripheral neuropathy J Neurol 249 1 9 17 1:CAS:528:DC%2BD38XisVKkt7k%3D 10.1007/PL00007853 11954874
7. CL Loprinzi K Maddocks-Christianson SL Wolf RD Rao PJ Dyck P Mantyh PJ Dyck 2007 The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism Cancer J 13 6 399 403 10.1097/PPO.0b013e31815a999b 18032978
8. M Martin A Rodriguez-Lescure A Ruiz E Alba L Calvo M Ruiz-Borrego B Munarriz CA Rodriguez C Crespo E de Alava, et al. 2008 Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer J Natl Cancer Inst 100 11 805 814 1:CAS:528:DC%2BD1cXmvFWksr0%3D 10.1093/jnci/djn151 18505968 (Pubitemid 351809668)
9. JA Sparano M Wang S Martino V Jones EA Perez T Saphner AC Wolff GW Sledge Jr WC Wood NE Davidson 2008 Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 16 1663 1671 1:CAS:528:DC%2BD1cXkslCitLk%3D 10.1056/NEJMoa0707056 18420499 (Pubitemid 351549913)
10. Cancer therapy evaluation program, common terminology Criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. Accessed 31 Mar, 2003
11. D Cella A Peterman S Hudgens K Webster MA Socinski 2003 Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-Taxane) Cancer 98 4 822 831 1:CAS:528:DC%2BD3sXntVWgurY%3D 10.1002/cncr.11578 12910528 (Pubitemid 36959280)
12. EA Calhoun DA Fishman PY Roland 2000 Validity and sensitivity of the functional assessment of cancer therapy/Gynecologic oncology group-neurotoxicity (FACT/GOG-Ntx) Proc Am Soc Clin Oncol 19 2000
13. DF Cella DS Tulsky G Gray B Sarafian E Linn A Bonomi M Silberman SB Yellen P Winicour J Brannon, et al. 1993 The functional assessment of cancer therapy scale: development and validation of the general measure J Clin Oncol 11 3 570 579 1:STN:280:DyaK3s7oslKqsQ%3D%3D 8445433
14. HQ Huang MF Brady D Cella G Fleming 2007 Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study Int J Gynecol Cancer 17 2 387 393 1:STN:280:DC%2BD2s7mtF2gsg%3D%3D 10.1111/j.1525-1438.2007.00794.x 17362317 (Pubitemid 46426765)
15. W Drobek A De Laat J Schoenaers 2001 Tactile threshold and pressure pain threshold during treatment of orofacial pain: an explorative study Clin Oral Investig 5 3 185 193 1:STN:280:DC%2BD3Mrmt1Crsw%3D%3D 10.1007/s007840100125 11642564
16. JM Goldberg U Lindblom 1979 Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation J Neurol Neurosurg Psychiatr 42 9 793 803 1:STN:280:DyaL3c%2FltFartg%3D%3D 10.1136/jnnp.42.9.793 501379
17. EK Rowinsky WA Flood SE Sartorius MK Bowling J Wagner DS Ettinger 1995 Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer Semin Oncol 22 4 Suppl 9 48 54 1:CAS:528:DyaK2MXosVCht78%3D 7644928
18. G Cavaletti E Cavalletti N Oggioni C Sottani C Minoia M D'Incalci M Zucchetti P Marmiroli G Tredici 2000 Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration Neurotoxicology 21 3 389 393 1:CAS:528:DC%2BD3cXltFSitL4%3D 10894128
19. Z Sahenk R Barohn P New JR Mendell 1994 Taxol neuropathy electrodiagnostic and sural nerve biopsy findings Arch Neurol 51 7 726 729 1:STN:280:DyaK2c3ovVOlsw%3D%3D 7912506
20. Y Schmidt JW Unger I Bartke R Reiter 1995 Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice Exp Neurol 132 1 16 23 1:CAS:528:DyaK2MXlvFCqur8%3D 10.1016/0014-4886(95)90054-3 7536686
21. SC Apfel RB Lipton JC Arezzo JA Kessler 1991 Nerve growth factor prevents toxic neuropathy in mice Ann Neurol 29 1 87 90 1:CAS:528:DyaK3MXlt1ygsL4%3D 10.1002/ana.410290115 1705109
22. G Cavaletti G Bogliun L Marzorati A Zincone M Piatti N Colombo D Franchi MT La Presa A Lissoni A Buda, et al. 2004 Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy Ann Oncol 15 9 1439 1442 1:STN:280:DC%2BD2cvhsVerug%3D%3D 10.1093/annonc/mdh348 15319252 (Pubitemid 39295034)
23. L Aloe L Manni F Properzi S De Santis M Fiore 2000 Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis Auton Neurosci 86 1-2 84 93 1:CAS:528:DC%2BD3MXmtVWntA%3D%3D 10.1016/S1566-0702(00)00247-2 11269929
24. CC Verstappen JJ Heimans K Hoekman TJ Postma 2003 Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management Drugs 63 15 1549 1563 1:CAS:528:DC%2BD3sXntFGhurY%3D 10.2165/00003495-200363150-00003 12887262 (Pubitemid 36976138)
25. TJ Postma JJ Heimans MJ Muller GJ Ossenkoppele JB Vermorken NK Aaronson 1998 Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy Ann Oncol 9 7 739 744 1:STN:280:DyaK1cvhtFOmtQ%3D%3D 10.1023/A:1008344507482 9739440 (Pubitemid 28394160)
26. MD Brundage JL Pater B Zee 1993 Assessing the reliability of two toxicity scales: implications for interpreting toxicity data J Natl Cancer Inst 85 14 1138 1148 1:STN:280:DyaK3szgvVOnug%3D%3D 10.1093/jnci/85.14.1138 8320743
27. K Shimozuma Y Ohashi A Takeuchi T Aranishi S Morita K Kuroi S Ohsumi H Makino H Mukai N Katsumata, et al. 2009 Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02 Support Care Cancer 17 12 1483 1491 10.1007/s00520-009-0613-7 19330359
28. TJ Postma NK Aaronson JJ Heimans MJ Muller JG Hildebrand JY Delattre K Hoang-Xuan M Lanteri-Minet R Grant R Huddart, et al. 2005 The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20 Eur J Cancer 41 8 1135 1139 1:STN:280: DC%2BD2M3mvVOmsQ%3D%3D 10.1016/j.ejca.2005.02.012 15911236 (Pubitemid 40725571)
29. G Cavaletti S Jann A Pace R Plasmati G Siciliano C Briani D Cocito L Padua E Ghiglione M Manicone, et al. 2006 Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity J Peripher Nerv Syst 11 2 135 141 1:CAS:528:DC%2BD28XntFaltrg%3D 10.1111/j.1085-9489.2006. 00078.x 16787511 (Pubitemid 43894080)
30. LM Thornton WE Carson 3rd CL Shapiro WB Farrar BL Andersen 2008 Delayed emotional recovery after taxane-based chemotherapy Cancer 113 3 638 647 1:CAS:528:DC%2BD1cXpvVWnsL0%3D 10.1002/cncr.23589 18521922
31. J Kopec S Land R Cecchini 2006 Validation of self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin J of Supp Oncol 4 W1 W8
32. EA Calhoun EE Welshman CH Chang JR Lurain DA Fishman TL Hunt D Cella 2003 Psychometric evaluation of the functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy Int J Gynecol Cancer 13 6 741 748 1:STN:280:DC%2BD3srpsVCjsw%3D%3D 10.1111/j.1525-1438.2003.13603.x 14675309 (Pubitemid 38235217)
33. A Hegarty RK Portenoy 1994 Pharmacotherapy of neuropathic pain Semin Neurol 14 3 213 224 1:STN:280:DyaK2M3hsFKgug%3D%3D 10.1055/s-2008-1041080 7701122
34. AA Argyriou E Chroni A Koutras G Iconomou S Papapetropoulos P Polychronopoulos HP Kalofonos 2006 Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation J Pain Symptom Manage 32 3 237 244 1:CAS:528:DC%2BD28XhtVyqu7bK 10.1016/j.jpainsymman.2006.03.013 16939848 (Pubitemid 44308452)
35. AA Argyriou E Chroni A Koutras J Ellul S Papapetropoulos G Katsoulas G Iconomou HP Kalofonos 2005 Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial Neurology 64 1 26 31 1:CAS:528:DC%2BD2cXhtFeisr7P 15642899 (Pubitemid 40082932)
36. S von Delius F Eckel S Wagenpfeil M Mayr K Stock F Kullmann F Obermeier J Erdmann R Schmelz S Quasthoff, et al. 2007 Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study Invest new drugs 25 2 173 180 10.1007/s10637-006-9010-y (Pubitemid 46020877)
37. RD Rao JC Michalak JA Sloan CL Loprinzi GS Soori DA Nikcevich DO Warner P Novotny LA Kutteh GY Wong 2007 Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3) Cancer 110 9 2110 2118 1:CAS:528:DC%2BD2sXhtlertbvN 10.1002/cncr.23008 17853395 (Pubitemid 350036873)
38. WS Wang JK Lin TC Lin WS Chen JK Jiang HS Wang TJ Chiou JH Liu CC Yen PM Chen 2007 Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients Oncologist 12 3 312 319 1:CAS:528:DC%2BD2sXlsVSqtbg%3D 10.1634/theoncologist.12-3-312 17405895 (Pubitemid 46556797)
39. S Cascinu V Catalano L Cordella R Labianca P Giordani AM Baldelli GD Beretta E Ubiali G Catalano 2002 Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial J Clin Oncol 20 16 3478 3483 1:CAS:528:DC%2BD38XntVyjtr4%3D 10.1200/JCO.2002.07.061 12177109
40. S Cascinu L Cordella E Del Ferro M Fronzoni G Catalano 1995 Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial J Clin Oncol 13 1 26 32 1:STN:280:DyaK2M%2Fps12mtw%3D%3D 7799029